Orasis Pharmaceuticals
Ponte Vedra
About Orasis Pharmaceuticals
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, and easy-to-use.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $126.0M
- Funding stage: Late Stage Venture
- Last round: Series Unknown (Oct 2024)
- Website: orasis-pharma.com
- Phone: +972-9-8877745
Industries & Categories
Clinical Trials, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/orasis-pharmaceuticals-5626 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.